FDA Approves New Psoriasis Drug
Siliq will be used to treat adults with moderate-to-severe plaque psoriasis
According to a news release, the FDA has approved Siliq to treat adults with moderate-to-severe plaque psoriasis. It is administered as an injection.
The drug will be used by patients for whom other methods, such as systemic therapy and phototherapy, have failed.
"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today’s approval provides patients with another treatment option for their psoriasis," said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. "Patients and their health care providers should discuss the benefits and risks of Siliq before considering treatment."
Siliq’s active ingredient, brodalumab, binds to a protein that causes inflammation, preventing it from occurring.